[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-kidney-disease-stage-3\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-kidney-disease-stage-3":67},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,52,77,108,133,162],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":34,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100641620","phase-2-reducing-inflammation-to-improve-vascular-and-bone-outcomes-with-low-dose-colchicine-in-ckd-100641620",false,"NCT07654231","Reducing Inflammation to Improve Vascular and Bone Outcomes With Low-dose Colchicine in CKD","Reducing Inflammation to Improve Vascular and Bone Outcomes With Low-dose Colchicine in CKD: A Pilot Randomized Open-Label Trial (RESOLVE-CKD Trial)","RESOLVE-CKD","Inclusion Criteria:\n\n* Men and women aged 18-\\\u003C70 years of all race\u002Fethnicity groups\n* CKD stage 3 (estimated glomerular filtration rate (eGFR) \\>30 to 59 ml\u002Fmin\u002F1.73m2)\n* Urine albumin-to-creatinine ratio (uACR) ≥ 200 mg\u002Fg\n* Cardiac artery calcification (CAC) Agatston score ≥30\n* Hypertension, diabetes, dyslipidemia, or established atherosclerotic cardiovascular disease (ASCVD) (coronary artery disease (CAD), ischemic stroke, and peripheral artery disease), defined by self-report, ICD-10 codes, or the use of medications for these conditions.\n* Ability to provide informed consent.\n\nExclusion Criteria:\n\n* Current Colchicine therapy\n* Hepatic disease\n* Any clinically active diagnosed infection requiring systemic antimicrobial therapy, positive microbiologic evidence of infection, or infection-related hospitalization within 30 days prior to study enrollment.\n* Immunosuppression\n* Current use of chemotherapy drugs or active cancer\n* Pregnancy\u002Fbreastfeeding\n* Hospitalized within the past 6 months\n* Allergic\u002Fintolerance to colchicine\n* Use of P-glycoprotein (p-gp) inhibitor (such as Verapamil, Quinidine, Amiodarone, Ritonavir, Lopinavir\u002Fritonavir, Saquinavir, Nelfinavir)\n* Use of strong cytochrome P450 3A4 (CYP3A4) inhibitors (such as Ketoconazole, Itraconazole, Posaconazole, Voriconazole, Clarithromycin, Erythromycin)\n* Human immunodeficiency virus (HIV) infection\n* Gout attack ≥ 1 time per year\n* Severe anemia (hemoglobin \\\u003C 8 g\u002Fdl for women and \\\u003C 9 g\u002Fdl for men)\n* eGFR \\\u003C30 ml\u002Fmin\u002F1.73m2\n* uACR \\\u003C200 mg\u002Fg\n* White blood cell count (WBC) \\\u003C3.0 x109\u002FL\n* Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \\> 3 x Upper Limit of Normal (ULN)\n* Total bilirubin \\>2 x ULN\n* Glucose \\>300mg\u002Fdl\n* Uses nicotine products or other recreational drugs\n* Unable to read or speak English\n* Participant in other conflict clinical trial,\n* Unable to complete the study measurements\n* Unable to undergo to computed tomography (CT) or dual-energy X-ray absorptiometry (DXA) scans\n* Unsafe to participate in this study per investigator's judgement.","ALL","18 Years","69 Years",{"count":21,"type":22},60,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","The overall objective of this pilot randomized clinical trial is to determine whether low-dose Colchicine (LoDoCo) improves vascular disease including vascular calcification, peripheral arterial disease (PAD), and chronic kidney disease-mineral and bone disorder (CKD-MBD) biomarkers in patients with chronic kidney disease (CKD) stage 3 over a 12-month intervention period, compared with usual care.\n\nSuccessful completion of this study will generate critical preliminary data to support a larger clinical trial aimed at evaluating inflammation-targeted therapies to mitigate CKD-MBD, including vascular calcification and related PAD, as well as osteoporosis, ultimately reducing cardiovascular events and mortality in patients with CKD. Additionally, this work has the potential to redefine the diagnostic framework for CKD-MBD.",[28,29,30,31,32,33],"Chronic Kidney Disease Mineral and Bone Disorder","Hypertension","Diabetes","Dyslipidemia","Atherosclerotic Cardiovascular Disease (ASCVD)","Chronic Kidney Disease (Stage 3)",[35,36,37,38],"Chronic Kidney Disease","CVD","vascular calcification","Colchicine","NOT_YET_RECRUITING","2026-06-17",{"date":42,"type":43},"2026-06-22","ACTUAL",{"date":45,"type":22},"2026-07-01",{"date":47,"type":22},"2027-12-31",{"name":49,"class":50},"University of Texas Southwestern Medical Center","OTHER",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":17,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":4,"studyType":23,"phases":63,"briefSummary":65,"conditions":66,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":73,"leadSponsor":75,"locationsCount":51},"100601067","effects-of-replacing-high-protein-foods-in-people-with-chronic-kidney-disease-100601067","NCT07105670","Effects of Replacing High Protein Foods in People With Chronic Kidney Disease","The Effects of Replacing Red Meat With Alternative Protein Sources on Gut-Derived Metabolites in People With Chronic Kidney Disease","Inclusion Criteria:\n\n* Age 40-70 years\n* Male or postmenopausal female\n* Stage 3 CKD (eGFR between 30-59ml\u002Fmin\u002F1.73m\\^2 by the CKD-EPI equation (without race correction)).\n* If eGFR is greater than or equal to 45ml\u002Fmin\u002F1.73m\\^2 then albuminuria must be greater than 300mg\u002Fg creatinine by spot urine.\n* Willing to consume controlled diet for duration of the study\n* Willing to collect fecal samples at home\n\nExclusion Criteria:\n\n* Hemoglobin A1c greater than 7% within previous six months\n* Treatment with metformin or insulin within previous three months\n* Blood pressure greater than 150\u002F100 mmHg from chart of home on at least two occasions in prior month (can be inclusive of screening visit)\n* Change in cardiovascular and\u002For hypertension medication in the last 30 days\n* History of major gastrointestinal disease (e.g. inflammatory bowel disease, uncontrolled irritable bowel syndrome, C. difficile chronic infection, celiac disease, diverticulitis, stomach or duodenal ulcers)\n* Known HIV disease\n* Hospitalization in the last two months\n* Significant recent unintentional weight loss (5% of weight over past three months)\n* Cancer or received cancer treatment in the last year (except basal cell carcinoma)\n* Prior bariatric surgery (i.e. gastric bypass, sleeve gastrectomy) or restrictive bariatric surgery (i.e. adjustable gastric band)\n* Treatment with immunosuppressive medications in the past six months or more than one week of treatment with prednisone greater than 10mg per day in the past three months (or equivalent steroid dose of non-prednisone steroids)\n* Recent antibiotic use defined as a single course of antibiotics within the past three months or two or more courses within the past six months\n* Known food allergy that would influence the ability to consume the study diets\n* History of hyperkalemia defined as greater than 5.5mmol\u002FL on at least two occasions\n* Other medical conditions or concerns at the discretion of the investigators","40 Years","70 Years",{"count":62,"type":22},15,[64],"NA","The goal of this crossover clinical trial is to explore the effects of red meat intake on serum and fractional urinary excretion of uremic toxins including trimethylamine N-oxide in people with chronic kidney disease.",[67],"Chronic Kidney Disease Stage 3","RECRUITING","2026-06-02",{"date":71,"type":43},"2026-06-04",{"date":45,"type":22},{"date":74,"type":22},"2027-06-30",{"name":76,"class":50},"Indiana University",{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":17,"minAge":85,"maxAge":86,"enrollmentInfo":87,"targetDuration":4,"studyType":23,"phases":89,"briefSummary":91,"conditions":92,"keywords":93,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":107},"100571506","phase-1-a-study-to-investigate-the-safety-tolerability-and-preliminary-efficacy-with-aion-301-administered-by-intravenous-infusion-compared-with-placebo-administered-by-intravenous-infusion-investigational-intervention-in-participants-aged-35-to-75-years-of-age-with-chronic-kidney-disease-ckd-100571506","NCT06721143","A Study to Investigate the Safety, Tolerability, and Preliminary Efficacy With AION-301 Administered by Intravenous Infusion Compared With Placebo Administered by Intravenous Infusion Investigational Intervention in Participants Aged 35 to 75 Years of Age With Chronic Kidney Disease (CKD)","A Double-blinded, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of AION-301 Administered by Intravenous Infusion for the Treatment of Participants With Stage 3 Chronic Kidney Disease","UC-MSC-CKD","Inclusion Criteria:\n\nParticipants are eligible to be included in the study only if all of the following criteria apply:\n\n* Patient is able to communicate well with the investigator, is capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol, understands all requirements of the study, and understands and signs the written ICF before any study-specific procedure.\n* Willing and able to comply with the scheduled visits and treatment plan.\n* Either biological sex\n* Participant must be 35 to 75 years of age inclusive, at the time of signing the informed consent.\n* Diagnosis of CKD stage 3, G3 (a and b): persistent eGFR between 30 and 59 mL\u002Fmin\u002F1.73 m² (at least 2 measures within that range in the preceding 3 months, including the one at screening visit), and persistent increased Albuminuria (at least 2 measures within 3 months, including 1 before screening and 1 at screening (criterion for increased Albuminuria at screening: ≥2 out of 3 repeat daily early morning samples at screening) (UACR ≥ 200 mg\u002Fg and \\\u003C than 5000 mg\u002Fg)\n* Treatment with maximum labelled or tolerated dose of a renin-angiotensin-aldosterone system (RAAS) blocking agent including an angiotensin converting enzyme (ACE) inhibitor or an angiotensin II receptor blocker (ARB), and SGLT2 inhibitors (SGLT2i) unless such treatment is contraindicated or not tolerated\\*. Treatment dose must be stable for at least 3 months prior to the date of the screening. If a patient is on treatment with GLP-1 receptor agonist, he\u002Fshe should be on a stable dose for at least 3 months before screening.\n\n  \\*Participants who are documented to be unable to take ACE inhibitors or ARBs or SGLT2i will be allowed to participate.\n* Female subjects must not be breastfeeding and must have no intention to become pregnant during the study, and she will be required to use at least two FDA approved birth control during the study. The FDA-approved and cleared methods for birth control are listed below:\n\n  * Permanent Sterilization\n  * Long-Acting Reversible Contraceptives (LARC)\n  * Contraceptive Injection\n  * Short-Acting Hormonal Methods\n  * Barrier Methods\n  * Emergency Contraception\n* Any male subject must agree to use contraceptives and not donate sperm during the study.\n* Contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.\n\nExclusion Criteria:\n\nParticipants are excluded from the study if any of the following criteria apply:\n\n* Prior transplant of any organ (including BM and stem cell transplant) or kidney transplant scheduled in the next 6 months.\n* Proteinuria\\>5000 and or serum Albumin\\\u003C 2.5 g\u002Fdl.\n* Acute coronary syndrome, stroke or TIA or hospitalization for heart failure in previous 12 weeks or poorly controlled hypertension (≥160\u002F100 mmHg at screening visit) or SBP\\\u003C90 at screening visit.\n* History of malignancy (except successfully treated squamous and basal cells skin carcinoma) within 5 years of screening.\n* History of atrial fibrillation (AF, AFib).\n* CKD due to genetic disorder.\n* History of systemic Autoimmune diseases like T1D, SLE or CKD caused by any autoimmune kidney disease.\n* Acute Kidney Injury (AKI) defined as increase in serum creatinine ≥1.5 times baseline in the previous 3 months or by presence of acute tubular injury in kidney biopsy in the previous 3 months.\n* Dialysis for acute renal failure within 12 weeks of screening visit.\n* Rapidly progressive kidney disease (eGFR reduction ≥ 30% over the last three months)\n* HbA1c ≥ 8.5%.\n* BMI ≥35 kg\u002Fm2.\n* Disorder of coagulation (including any history of thrombotic or thromboembolic disease) and\u002For long-term anti-coagulant therapy\n* History of Deep Vein Thrombosis (DVT)\n* History of Acute Pulmonary Embolism\n* History of solitary kidney.\n* On medications such as immunosuppressant, monoclonal antibodies, anabolic steroids, at the time of screening or in the previous 6 months and\u002For illicit drugs.\n* History of alcohol abuse or cigarette smoking in the previous 6 months.\n* Pregnancy or breast feeding at the time of screening, or with intention to become pregnant or breast-feeding during the course of the study, including the follow-up period.\n* History of liver disease, ALT and AST ≥3 x ULN, positive serology for Hepatitis B or Hepatitis C, HIV.\n* A significant medical history or abnormality at the physical exam that, in the judgment of the principal investigator, may interfere with the study.\n* Presence of any active infection, including COVID 19\n* Any clinically significant pulmonary disease\n* History of hypersensitivity to study drug and\u002For any of its excipients.\n* Close affiliation with the investigational site; for example, a close relative of the investigator, dependent person (for example employee or student of the investigational site).\n* Panel Reactive Antibodies (PRA) \\>0% (positive)","35 Years","75 Years",{"count":88,"type":22},36,[90,25],"PHASE1","The goal of this clinical trial is to learn about the safety (good or bad) of giving two AION-301 intravenous (IV) infusions, in adults with Stage 3 Chronic Kidney Disease (CKD). It will also help to learn if AION-301 reduces the symptoms of CKD and\u002For progression. The main questions it aims to answer are:\n\n* Do participants have medical problems (adverse events) after receiving two infusions of AION-301?\n* Do participants feel better (have reduced and\u002For delayed CKD symptoms)?\n* To learn about how AION-301 works in participants with CKD?\n\nResearchers will compare AION-301 to a placebo (a look-alike substance that contains no drug) to see if AION-301 works to treat Stage 3 CKD.\n\nParticipants will:\n\n* Receive two infusions of AION-301 or placebo on two separate days (Day 0 and Day 4).\n* Receive oral vitamins at the clinic and to take at home for 90 days.\n* Visit the clinic for a minimum of 9 times, over 6 months for checkups and tests, but could be up to 12 times, over 24 months for checkups and tests.",[67],[94,95,96,35],"CKD","AION-301","Stage 3 CKD","2026-03-27",{"date":99,"type":43},"2026-04-01",{"date":101,"type":43},"2025-01-23",{"date":103,"type":22},"2027-05",{"name":105,"class":106},"AION Healthspan, Inc.","INDUSTRY",2,{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":114,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":116,"targetDuration":4,"studyType":23,"phases":118,"briefSummary":119,"conditions":120,"keywords":122,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":131,"locationsCount":107},"100587194","closed-loop-impact-on-chronic-kidney-disease-in-type-2-diabetes-100587194","NCT06925217","Closed-Loop Impact on Chronic Kidney Disease in Type 2 Diabetes","The Effect of Fully Closed-loop Insulin Delivery on Renal Oxygenation in People With Type 2 Diabetes and Chronic Kidney Disease: an Open-label, Single-center, Randomized Two-arm Parallel Trial","CLICK","Inclusion Criteria:\n\n* Informed consent signed by the subject\n* Age 18 years and older\n* Type 2 diabetes diagnosed for at least 12 months\n* Treatment with insulin therapy for at least 6 months\n* CKD defined either as an eGFR 30-59 ml\u002Fmin\u002F1.73m² or presence of albuminuria \\> 3 mg\u002Fmmol (stage A2 or A3 according to KDIGO) with an eGFR \\> 30 ml\u002Fmin\u002F1.73m². CKD must be present for at least 6 months.\n* HbA1c \\\u003C 12% based on a venous blood sample from the screening visit\n* Receiving treatment with an SGLT2 inhibitor and\u002For GLP-1 receptor agonist for at least 3 months, have been offered these therapies previously, or contraindication\u002Fintolerance to receiving these therapies\n* Willing to wear study devices and follow study instructions\n* Capable of giving an informed consent\n\nExclusion Criteria:\n\n* Type 1 diabetes\n* Current use of insulin pump\n* Current use of any closed-loop system\n* Alternative cause of CKD according to medical records such as polycystic kidney disease, glomerulonephritis, congenital urogenital tract diseases, etc.\n* Known or suspected allergy against insulin\n* Pregnancy, planned pregnancy, or breast feeding\n* Severe visual impairment\n* Severe hearing impairment\n* Two or more episodes of severe hypoglycemia in the last 6 months\n* Medically documented allergy towards the adhesive (glue) of plasters\n* Serious skin diseases located at places of the body, which potentially are possible to be used for localisation of the glucose sensor\n* Any physical\u002Fpsychological disease or medication(s) likely to interfere with the conduct of the study and interpretation of the study results, as judged by study clinician\n* Recent (less than three months) history of myocardial infarction, percutaneous coronary intervention, stroke, or hospitalization for heart failure with reduced ejection fraction\n* History of renal transplantation requiring ongoing immunosuppressive therapy\n* Known or suspected non-compliance, drug or alcohol abuse\n* Inability to follow the procedures of the investigation, e.g. due to language problems\n* Incapacity to give informed consent\n* Contra-indication to undergo MR-imaging according to a standard checklist such as the presence of a pacemaker or other implanted metallic device or severe claustrophobia.\n* Subject refuses to be informed of incidental findings related to their health discovered during imaging or other study-related exams\n* Participation in another investigation with an investigational drug or another MD within the 30 days preceding and during the present investigation\n* Previous enrolment into the current investigation\n* Enrolment of the PI, his\u002Fher family members, employees and other dependent persons",{"count":117,"type":22},76,[64],"The main objective of this study is to evaluate the effect of fully automated closed-loop glucose control on renal tissue oxygenation among people with type 2 diabetes and chronic kidney disease.\n\nThis is a single-center, open-label parallel design study that will compare 26 weeks of fully-automated closed-loop glucose control with standard insulin therapy and continuous glucose monitoring, following a run-in period. A total of up to 76 adults with type 2 diabetes and chronic kidney disease will be recruited through outpatient diabetes and nephrology clinics.\n\nThe primary outcome is renal tissue oxygenation measured using blood oxygenation level-dependent magnetic resonance imaging at 26 weeks. Other key outcomes include glycated hemoglobin at 26 weeks and time spent with glucose levels within and above the target glucose range (3.9-10.0mmol\u002FL). Other glycemic and renal outcomes (including renal function) will also be assessed, as well as patient-reported outcome measures using validated questionnaires. Safety evaluations include severe hypoglycemic episodes and other adverse and serious adverse events.",[121,67],"Type 2 Diabetes",[123,124],"closed-loop","type 2 diabetes","2026-02-11",{"date":127,"type":43},"2026-02-12",{"date":129,"type":43},"2025-06-16",{"date":103,"type":22},{"name":132,"class":50},"Heba Al-Alwan",{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":137,"acronym":138,"eligibilityCriteria":139,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":140,"targetDuration":4,"studyType":142,"phases":4,"briefSummary":143,"conditions":144,"keywords":145,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":51},"100572367","urinary-tubular-biomarkers-for-chronic-kidney-disease-100572367","NCT06732349","Urinary Tubular Biomarkers for Chronic Kidney Disease","U-Tube 1","Inclusion Criteria:\n\n* Chronic kidney disease stage 3 (eGFR 30-59ml\u002Fmin)\n\nExclusion Criteria:\n\n* Active glomerulonephritis treated with immunosuppression\n* Kidney transplant recipient\n* Current treatment with chemo- or immunotherapy for malignancy",{"count":141,"type":22},556,"OBSERVATIONAL","Currently used tests for chronic kidney injury only assess the function of one part of the kidney: the filter called the glomerulus. The other part, called the tubule, is disregarded. Based on many previous studies, the investigators have good reason to assume that a better prediction of the course of chronic kidney disease by testing tubular function will be possible. This is important, for example, when patients need to be treated with kidney-protecting drugs.",[67],[146,147,148,149,150,151,152],"biomarker","disease progression","chronic kidney disease","tubular function and injury","urine","risk assessment","personalized medicine","2025-08-06",{"date":155,"type":43},"2025-08-07",{"date":157,"type":43},"2025-01-01",{"date":159,"type":22},"2029-12",{"name":161,"class":50},"Erasmus Medical Center",{"id":163,"slug":164,"hasResults":11,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":4,"eligibilityCriteria":168,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":169,"targetDuration":4,"studyType":23,"phases":171,"briefSummary":172,"conditions":173,"keywords":176,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":51},"100589627","clinical-effectiveness-of-mynutrikidney-100589627","NCT06956872","Clinical Effectiveness of MyNutriKidney®","Clinical Effectiveness of MyNutriKidney® for Dietary Self-management in Chronic Kidney Disease Patients: Protocol for a Pragmatic Randomized Controlled Trial","Participants must meet all of the following inclusion criteria and none of the exclusion criteria to be eligible for enrolment into the study.\n\nInclusion Criteria:\n\n1. Clinically diagnosed Chronic Kidney Disease (CKD):\n\n   1.1. eGFR \\\u003C 60 ml\u002Fmin\u002F1.73m² for ≥ 3 months (applicable to pre-dialysis patients, Stages 3-5)\n2. Aged 18 years or older.\n3. Possesses a personal smartphone compatible with the MyNutriKidney® application and is willing to use the health app if randomized to the intervention group.\n4. Alert and oriented, and deemed capable of providing informed consent and participating in study procedures.\n5. Able to communicate and understand study procedures in English, Bahasa Melayu, or Mandarin.\n\nExclusion Criteria:\n\n1. Inability to effectively use the smartphone application due to significant impairments (e.g., severe visual or motor problems).\n2. Smartphone owned by the participant does not meet the minimum technical requirements for the MyNutriKidney® application installation and operation\n3. Presence of significant cognitive impairment or severe psychological conditions (e.g., uncontrolled anxiety or depression) likely to impede consistent participation or adherence to study requirements.\n4. Known unwillingness or inability to comply with core study procedures, including dietary assessment components.\n5. Concurrent participation in another interventional research study.\n6. Participation in another research study involving an investigational product in the 12 weeks preceding potential enrollment.\n7. Female participants who are pregnant, currently lactating, or planning a pregnancy during the course of the trial.\n8. Currently receiving primary nutritional support via enteral tube feeding or parenteral (intra-venous) nutrition.\n9. Currently receiving active treatment for cancer (e.g., chemotherapy, radiotherapy).",{"count":170,"type":22},200,[64],"This study is a 6-month, pragmatic, multi-center, sequentially recruited, stratified, open-label randomized controlled trial (RCT) conducted in Malaysia. It aims to determine the clinical effectiveness of a culturally adapted, gamified mobile health app (MyNutriKidney®) supplementing standard care, compared to standard care alone, for improving dietary self-management among 200 adults with Chronic Kidney Disease (CKD) stages 3-5. Participants will be randomly assigned (1:1, stratified by age and education) into either (i) the intervention group (MyNutriKidney® app + standard care) or (ii) the control group (standard care, including routine dietary counseling and printed materials). The co-primary outcomes are changes in Dietary Adherence (measured by CKD Diet Score) and Nutrition Literacy (measured by NLS score) from baseline to 6 months.",[67,35,174,175],"Chronic Kidney Disease Stage 5","Chronic Kidney Disease Stage 4",[177,148,94,178,179,180,181,182,183,184,185,186,187],"MyNutriKidney","Dietary Adherence","Nutrition Literacy","Self-management","Mobile Health","Dietitian","mHealth","Telemedicine","Digital Health","Malaysia","Kidney Diseases","2025-05-01",{"date":190,"type":43},"2025-05-04",{"date":192,"type":22},"2025-07-01",{"date":194,"type":22},"2027-02-01",{"name":196,"class":50},"Universiti Putra Malaysia"]